|  |  |
| --- | --- |
| **Supplementary Table 2**. Clinicopathologic Characteristics of Sorafenib positive HCC patients | |
| Characteristics | No. of patients |
| Patients | 32 |
| Age, y |  |
| ≤50 | 13 |
| >50 | 19 |
| Sex |  |
| Male | 20 |
| Female | 12 |
| AFP, ng/mL |  |
| ≤20 | 11 |
| >20 | 21 |
| TNM staging |  |
| I | 17 |
| II | 13 |
| III | 2 |
| Tumor size, cm |  |
| ≤5 | 23 |
| >5 | 9 |
| Tumor number |  |
| Single | 14 |
| Multiple | 18 |
| Microvascular invasion |  |
| Yes | 13 |
| No | 19 |
| Macrovascular invasion |  |
| Yes | 5 |
| No | 27 |
| Hepatitis B virus DNA |  |
| ≤1000 IU/mL | 15 |
| >1000 IU/mL | 17 |
| Cirrhosis |  |
| Yes | 21 |
| No | 11 |
| Differentiation |  |
| Ⅰ | 6 |
| II | 11 |
| III | 13 |
| Ⅳ | 2 |
| BCLC |  |
| A | 17 |
| B | 11 |
| C | 4 |
| AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging. | |